Vanguard Group’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-1,117,826
| Closed | -$3.32M | – | 4113 |
|
|
2016
Q3 | $3.32M | Sell |
1,117,826
-50,365
| -4% | -$87.3K | ﹤0.01% | 3185 |
|
|
2016
Q2 | $1.74M | Sell |
1,168,191
-522,573
| -31% | -$1.2M | ﹤0.01% | 3417 |
|
|
2016
Q1 | $6.26M | Sell |
1,690,764
-283,980
| -14% | -$1.76M | ﹤0.01% | 2842 |
|
|
2015
Q4 | $19.9M | Buy |
1,974,744
+86,965
| +5% | +$1.05M | ﹤0.01% | 2306 |
|
|
2015
Q3 | $25.7M | Buy |
1,887,779
+37,066
| +2% | +$660K | ﹤0.01% | 2179 |
|
|
2015
Q2 | $35.1M | Buy |
1,850,713
+56,441
| +3% | +$1.22M | ﹤0.01% | 2112 |
|
|
2015
Q1 | $47M | Buy |
1,794,272
+129,582
| +8% | +$3.3M | ﹤0.01% | 1944 |
|
|
2014
Q4 | $34.9M | Buy |
1,664,690
+9,560
| +0.6% | +$241K | ﹤0.01% | 2007 |
|
|
2014
Q3 | $55.2M | Buy |
1,655,130
+32,424
| +2% | +$1.01M | ﹤0.01% | 1740 |
|
|
2014
Q2 | $52.1M | Buy |
1,622,706
+28,750
| +2% | +$1.07M | ﹤0.01% | 1811 |
|
|
2014
Q1 | $73.5M | Buy |
1,593,956
+115,805
| +8% | +$6.79M | 0.01% | 1573 |
|
|
2013
Q4 | $105M | Buy |
1,478,151
+118,060
| +9% | +$9.03M | 0.01% | 1289 |
|
|
2013
Q3 | $117M | Buy |
1,360,091
+470,535
| +53% | +$39.9M | 0.01% | 1140 |
|
|
2013
Q2 | $56.3M | Buy |
+889,556
| New | +$47.2M | 0.01% | 1551 |
|
Vanguard Group's AEGR Position: Q4 2016 in Review
Vanguard Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 1,117,826 shares — an estimated $3.32M sold.
Vanguard Group first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $117M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Vanguard Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Vanguard Group sold 1,117,826 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $3.32M.
- Vanguard Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Vanguard Group's Aegerion Pharmaceuticals position peaked at $117M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.